Switch theme
Sign up to access all valuation multiples
Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI.
2015
n/a
LTM Revenue n/a
LTM EBITDA n/a
$88.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oncocross has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Oncocross achieved revenue of $0.7M and an EBITDA of -$4.1M.
Oncocross expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncocross valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.7M | XXX | XXX | XXX |
| Gross Profit | $24K | $3K | XXX | XXX | XXX |
| Gross Margin | 38% | 0% | XXX | XXX | XXX |
| EBITDA | -$2.5M | -$4.1M | XXX | XXX | XXX |
| EBITDA Margin | -3966% | -565% | XXX | XXX | XXX |
| Net Profit | -$7.0M | -$2.9M | XXX | XXX | XXX |
| Net Margin | -11149% | -393% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oncocross's stock price is KRW 12630 (or $9).
Oncocross has current market cap of KRW 150B (or $102M), and EV of KRW 130B (or $88.3M).
See Oncocross trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $88.3M | $102M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oncocross has market cap of $102M and EV of $88.3M.
Oncocross's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Oncocross's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oncocross and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $88.3M | XXX | XXX | XXX |
| EV/Revenue | 120.8x | XXX | XXX | XXX |
| EV/EBITDA | -21.4x | XXX | XXX | XXX |
| P/E | -23.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -22.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOncocross's NTM/LTM revenue growth is n/a
Oncocross's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Oncocross's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oncocross's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oncocross and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1071% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -565% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 67% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 64% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 245% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 717% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncocross acquired XXX companies to date.
Last acquisition by Oncocross was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncocross acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oncocross founded? | Oncocross was founded in 2015. |
| Where is Oncocross headquartered? | Oncocross is headquartered in South Korea. |
| Is Oncocross publicy listed? | Yes, Oncocross is a public company listed on KRX. |
| What is the stock symbol of Oncocross? | Oncocross trades under 382150 ticker. |
| When did Oncocross go public? | Oncocross went public in 2024. |
| Who are competitors of Oncocross? | Similar companies to Oncocross include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Oncocross? | Oncocross's current market cap is $102M |
| What is the current revenue growth of Oncocross? | Oncocross revenue growth between 2023 and 2024 was 1071%. |
| Is Oncocross profitable? | Yes, Oncocross is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
